Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.1652W HIGH $44.73
Volume
69.81 K
Value Traded
613.71 K
Short % Float
0.13%
-3.52%Week
-28.42%1 Month
-53.26%3 Month
-83.67%6 Month
+518.25%5 Year
+518.25%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
670.53 M
EPS (TTM)
0.16
P/E Ratio
28.47
Ent. Value
4.67 B
Total Shares
143.89 M
Float Shares
39.69 M
Insiders
9.57%
Institutions
0.16%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NNNN Catalyst Timeline
Dated clinical, regulatory and corporate events for Anbio Biotechnology
Past FDA Catalysts and PDUFA Decisions
How NNNN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Anbio Biotechnology is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every NNNN program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NNNN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NNNN for Q2 2026. | ||||
NNNN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NNNN ranks across every disease it competes in
Competitive Position is a premium feature
See how NNNN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNNNN News
NNNNAnbio Biotechnology Friedrich-Ebert-Anlage 35-37, 60327 Frankfurt am Main, Germany PROXY STATEMENT AND NOTICE OF A MEETING OF THE HOLDERS OF CLASS A
Anbio Biotechnology has announced a proxy statement and notice for a meeting for the holders of Class A Ordinary Shares scheduled for May 15, 2026, in Frankfurt, Germany. The meeting aims to vote on a proposal that includes changes to the company's share capital structure and voting rights among other matters. Shareholders of record as of April 22, 2026, are entitled to attend and participate in the vote. An extraordinary general meeting will follow immediately after the Class A Meeting to discuss additional proposals.
Read more →NNNNAnbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum
Anbio Biotechnology announced that its CEO will participate in the KeyBanc Capital Markets Virtual Healthcare Forum on March 18, 2026. During the event, the CEO will discuss business updates, strategic initiatives, and product development. This participation underscores Anbio's commitment to enhancing access to rapid diagnostics and advancing its innovative product offerings.
Read more →NNNN▼ -7.4%on this news
Anbio Biotechnology Announced Unaudited Financial Results for the Six Months Ended June 30, 2025
Anbio Biotechnology announced its unaudited financial results for the six months ending June 30, 2025, reporting a total revenue of approximately $4.6 million, down from $5.8 million in 2024. Despite the revenue decline, the company's gross profit increased markedly, achieving a gross margin of about 92.3%, up from 66.9%. The net income also rose to approximately $3.8 million compared to $3.6 million in the year prior. The company attributed the revenue drop to changes in its product mix as it focuses on higher-margin products and cost controls. Notably, a large proportion of IVD revenue was derived from non-COVID products, indicating a strategic shift in its offerings.
Read more →NNNN▲ +5.2%on this news
Driving Veterinary Healthcare Forward: Anbio Showcases Diagnostic Portfolio at WSAVA 2025
Anbio Biotechnology participated in the WSAVA 2025, showcasing its veterinary diagnostic portfolio. The event highlighted five product lines, including advanced molecular diagnostics capable of rapid results. Anbio's engagement with global partners underscored the demand for accessible testing technologies in veterinary healthcare. The company plans to continue its outreach at future events.
Read more →NNNN▲ +10.9%on this news
Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
Anbio Biotechnology has launched a Chikungunya IgM/IgG Rapid Test and the AP-100 Ultra-Fast PCR system to enhance outbreak response capabilities. The rapid test allows for quick detection of Chikungunya antibodies, while the AP-100 provides laboratory-grade PCR results in just 15 minutes. These advancements aim to improve public health responses to emerging infectious diseases.
Read more →NNNN▲ +6.1%on this news
Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions
Anbio Biotechnology is set to participate in three major international exhibitions in May 2025, showcasing its innovative in-vitro diagnostic technologies. The events include EuroMedLab 2025 in Brussels, AVA Conference 2025 in Sydney, and ACMTT 2025 in Bangkok. Anbio aims to expand its global presence and foster partnerships while promoting accessible and high-performance diagnostics.
Read more →NNNNAnbio Biotechnology Announces Closing of Initial Public Offering
Anbio Biotechnology announced the successful closing of its initial public offering, raising a total of US$8 million from the sale of 1,600,000 Class A ordinary shares at a price of US$5.00 each. The shares began trading on the Nasdaq Global Market under the ticker symbol 'NNNN.' Proceeds from the offering will be allocated towards expanding sales and distribution, research and development, as well as general corporate purposes. The offering was underwritten by AC Sunshine Securities LLC and marked a significant milestone for the company.
Read more →NNNNAnbio Biotechnology to Showcase Cutting-Edge Diagnostic Solutions at 2025 Medlab Middle East
Anbio Biotechnology will participate in the 2025 Medlab Middle East exhibition, showcasing its latest Point-of-Care Testing products. The event, held from February 3-6 at the Dubai World Trade Centre, is a key platform for medical professionals and distributors. Anbio aims to provide reliable and cost-effective diagnostic solutions to enhance healthcare outcomes.
Read more →NNNNAnbio Biotechnology Unveils Dry Chemiluminescence Immunoassay (CLIA) Solution: Redefining Diagnostic Precision and Efficiency
Anbio Biotechnology has launched its Dry Chemiluminescence Immunoassay (CLIA) Solution ADL-1000, which promises rapid and reliable diagnostic results. This innovative technology features freeze-dried reagents that eliminate cold chain logistics and incorporates advanced whole blood testing. The system is designed for efficiency, with a compact footprint and the capability to deliver results in as little as 15 minutes for critical assays.
Read more →NNNNAnbio Biotechnology Unveils Comprehensive In-Vitro-Diagnostics Solutions at ADLM 2024
Anbio Biotechnology made a significant impact at the 2024 ADLM conference by showcasing its extensive in vitro diagnostics solutions, featuring over 300 products. The company demonstrated real-world applications of its products in various healthcare settings and launched a new veterinary diagnostic solution. Anbio's commitment to R&D and product quality was highlighted, drawing attention from global clients.
Read more →NNNNAnbio Biotechnology to Showcase at ADLM 2024 with Evolved In Vitro Diagnostic Solutions
Anbio Biotechnology will participate in the ADLM 2024 Clinical Lab Expo from July 30 to August 1 in Chicago. The company plans to showcase its advanced point-of-care testing products, highlighting their accuracy and robustness. Anbio aims to make its diagnostic solutions accessible to a broader audience, reflecting its commitment to innovation in healthcare.
Read more →NNNNAnbio Biotechnology to Showcase ABO & Rhd Blood Grouping Kit at Medlab Middle East 2024
Anbio Biotechnology will showcase its ABO & Rhd Blood Grouping Kit at Medlab Middle East 2024 in Dubai. This innovative kit allows for quick blood type testing using a simple dot-filtration method, providing results in just one minute. It is designed for ease of use, requiring no special storage conditions, and targets markets in the Middle East, Asia, and Africa.
Read more →NNNNAnbio Biotechnology to Present at Medlab Middle East on February 5th, 2024.
Anbio Biotechnology will participate in Medlab Middle East from February 5 to 8, 2024, in Dubai. The event is a significant international exhibition for the medical laboratory industry. Anbio aims to establish partnerships and strengthen its presence in the Middle East by showcasing its in vitro diagnostic products. The company emphasizes innovation and accessibility in diagnostics.
Read more →NNNNAnbio Biotechnology Made a Successful First Presence at AACC Middle East 2023
Anbio Biotechnology successfully launched its in vitro diagnostic products at AACC Middle East 2023 in Dubai. The company showcased innovative solutions, including portable analyzers and various diagnostic assays. CEO Michael Lau highlighted the significance of this launch for Anbio's presence in the Middle East market and their commitment to quality products and partnerships.
Read more →NNNNAnbio Biotechnology to Present at AACC Middle East 2023 on October 7th, 2023
Anbio Biotechnology will participate in the AACC Middle East 2023 conference in Dubai on October 7-8, 2023. The event aims to enhance business cooperation in the region and showcase Anbio's innovative in vitro diagnostic solutions. The conference will cover various topics in laboratory medicine, emphasizing advancements in diagnostics.
Read more →NNNNAnbio Biotechnology Made a Successful Presence at Medic East Africa 2023
Anbio Biotechnology successfully exhibited at Medic East Africa 2023, showcasing innovative diagnostic solutions including the AF-100S analyzer, LAMP, and LFA assays. The AF-100S is a portable, user-friendly device designed for various settings, providing accurate results across a wide range of assays. Anbio's commitment to R&D aims to enhance healthcare diagnostics in Africa and globally.
Read more →NNNNAnbio Biotechnology to Present at Medic East Africa 2023 on September 13th, 2023
Anbio Biotechnology will present at Medic East Africa 2023 from September 13 to 15. The event, held at the Kenyatta International Convention Centre, is a key healthcare and medical laboratory gathering in East Africa. Anbio aims to enhance business partnerships and promote its diagnostic products in the region.
Read more →NNNNIntroducing the Anbio Lateral Flow Assay (LFA) Solution: Rapid Diagnostic for Laboratory, Point-of-Care, and At-Home Testing
Anbio has launched the Anbio Lateral Flow Assay (LFA) solution, a rapid diagnostic tool designed for laboratory, point-of-care, and at-home testing. This innovative product detects antigens and biomarkers with high specificity and sensitivity, providing results in just 20 minutes. It is aimed at early disease detection and mitigating the spread of infections.
Read more →NNNNAnbio Biotechnology Highlights the Future of Diagnostic Solutions at AACC 2023
Anbio Biotechnology successfully launched its in vitro diagnostic (IVD) products at the AACC 2023 Annual Scientific Meeting in Anaheim, CA. The company showcased various diagnostic solutions, including CLIA, FIA, and Lateral Flow products. CEO Michael Lau emphasized the importance of their affordable solutions for the North American market and future global partnerships during his lecture.
Read more →About Anbio Biotechnology
BIOPHARMAWATCH ELITE PLUS
Trade the next NNNN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime